Combat Medical

Highlighting best practice as a representative in The Parliamentary Review

The ability to listen and learn from one another has always been vital in parliament, in business and in most aspects of daily life. But at this particular moment in time, as national and global events continue to reiterate, it is uncommonly crucial that we forge new channels of communication and reinforce existing ones. The following article from Combat Medical is an attempt to do just that. We would welcome your thoughts on this or any other Parliamentary Review article.

CEO Edward Bruce-White
COMBAT HIVEC treatment
for bladder cancer
Combat Medical Ltd are helping to combat three of
the ten most common cancers with their patented
technology. Combat’s devices safely heat, recirculate
and deliver the chemotherapy agent directly to the body
cavity to target the cancer cells for maximum effect. The CE-
marked devices have the potential to save, extend or improve
millions of lives. Although Combat Medical are confident in
their future, there are many hurdles left for them to surmount,
as funding trials and new country registrations are both
costly and complex. Chief Executive Edward Bruce-White tells
TheParliamentary Review
more about this effort, how they have
succeeded thus far and what challenges are yet to come.
Our devices are available in 40 countries, routinely used in 200 hospitals worldwide,
including 30 NHS hospitals. Over 1,000 patients have been recruited onto clinical
trials, and efficacy data has been presented on over 1,500 patients for both devices.
Funding trials and expanding the R&D has been achieved through a collaboration
between the Combat team, medical professionals and specialistinvestors.
Bladder and peritoneal cancers, despite medical advances, are among the most
difficult cancers to treat and, in the case of bladder cancer, receive only 0.6 per cent
of National Cancer Research Institute funding. Among those affected with such
diseases, recurrence rates are still high, and the side effects of existing treatments
continue to present large problems. At Combat Medical, we have been working
hard to optimise current drug delivery. Our aim is to save and improve patient lives
by enhancing treatment efficacy without causing additional side effects.
»CEO: Edward Bruce-White
»Founded in 2012
»Located in Hertfordshire, UK
»Services: Medical devices and
»No. of employees: 30
»Our team in the UK head
office hail from 8 different
countries and, collectively,
speak over 15 languages
Combat Medical
Highlighting best practice
To be recommended in guidelines
and adopted, products need to be
clinically effective, affordable and easy
to integrate into current practice. We
are working hard to make robust,
safe, clinically effective and usable
products. Competing in this market
requires a vast range of resources, time
and investment, which is challenging
for smaller companies, no matter
how effective the treatments and
Innovation that saves lives
Our solution to helping combat
these cancers is a patented medical
device that delivers drugs directly to
the cavity via a closed recirculation
method at a precise temperature and
pressure. The optimum therapeutic
temperature for hyperthermia is 43
degrees celsius. Targeting cancer cells
in this way is effective because cancer
cells can’t manage the heat as well
as healthy cells. The cancer cells are
actively destroyed, while, at the same
time, the heat stimulates the body’s
own immune response to attack
these cells, recognise them and stop
Some drugs have also been shown to
be more active at 43 degrees celsius.
Exciting experimental studies have been
performed with hyperthermia, increasing
response rates of Check Point Inhibitors
PD-L1 drugs. The Combat BRS has been
shown to activate thermally sensitive
drugs, enabling the delivery of 17 times
more chemotherapy to the bladder
while limiting toxicity to other organs.
We’ve met stringent approval
requirements in the UK, Europe and
Australia and have recently treated
our first US patients. We have recently
been granted a humanitarian use
approval for Duke University in the
USA, allowing us to treat US patients.
The devices have been in clinical use
since 2011; we have invested in several
ongoing trials, and data is being
steadily released and will continue
to be released over the next three
years. Judging by our existing results,
collected in smaller trials and audited
and presented by hospitals, there is
good reason to be optimistic. Increases
in disease-free survival vary dramatically
depending on the type of cancer, but
results are already showing significant
improvements in patientoutcomes.
for bladder cancer treatment COMBAT PRS+ delivering HIPEC and
Agitation for peritoneal cancer treatments
Our aim is to
save and
patient lives
by enhancing
additional side
Ensuring our presence is
It’s not enough to have a good
product; it must fulfil a specific need,
and customers must be able to access
it via a strong sales and marketing
plan and effective distribution
channels. We have established a global
sales network, with 29 distributors
covering 40 countries. We work in
partnership with over 200 leading
hospitals globally and over 30 NHS
hospitals including leading UK
university hospitals, such as University
Hospitals of Leicester and University
College London Hospitals, as well as
organisations further afield, including
the Netherlands Cancer Institute and
Duke University in the US. We work
with cancer charities globally and
have also been selected as one of 30
UK companies to be awarded and
benefit from an Innovate UK scale-
up programme, which also led to the
award of a £1 million Innovate UK
grant to use the patented technology
to develop a new system for other
clinical indications.
To compete in this market, you must
fundamentally prove your clinical
results, which is why we have engaged
in such a comprehensive clinical
Navigating difficult terrain
Although our achievements so far
have been significant, there are huge
challenges for a start-up like Combat.
Acquiring the necessary investment
to innovate, grow, ensure compliance
in a highly regulated industry and
engage in clinical trials and new R&D
is expensive and, with a small team,
requires dedication and enthusiasm.
Keeping our small but highly skilled
team dedicated and motivated is even
harder in the current climate, as there is
– at the time of writing this – so much
uncertainty and additional planning
around Brexit. The cost implications for
a business such as ours are immense,
as we sell about 70 per cent of our
systems within Europe and rely on
speed efficiencies withindistribution.
Remembering why we do this and the
difference our systems and treatments
can make to patients is something
that keeps everyone in the company
motivated to succeed and to ensure as
many patients as possible can benefit
from our treatments. We continue to
focus on our mission of saving and
improving patient lives. As CEO, I feel
incredibly proud of the dedicated
efforts made by the whole team in
pursuit of this end goal.
We’ve met
requirements in
the UK, Europe
and Australia
and have
recently treated
our first US
PRS delivering HIPEC
treatment with agitation
Cancer cell under
increased attack

This article was sponsored by Combat Medical. The Parliamentary Review is wholly funded by the representatives who write for it.